Drug intelligence / Profile preview

levofloxacin + linezolid

Development stage: Preclinical
Lead developer: Johnson & Johnson Pharmaceutical Research & Development LLC
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Levofloxacin + linezolid is a combination of two antibiotics used to treat bacterial infections. Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of the 70S initiation complex. This combination has been studied for the treatment of multidrug-resistant tuberculosis (MDR-TB) and other serious bacterial infections.

Targets

DNA gyraseNeuraminidaseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on levofloxacin + linezolid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levofloxacin + linezolid.

Explore the full profile